On September 25, Revolution Medicines, Inc. rose 5.06% in regular trading, trading at $210.095 per share, with turnover of $192 million. The rally was fueled by a confluence of positive catalysts, including multiple investment bank price target upgrades and a recent FDA breakthrough therapy designation for the company's flagship drug.

On September 15, the FDA granted breakthrough therapy designation to Rasonque (daraxonrasib) plus chemotherapy for first-line treatment of metastatic pancreatic cancer, significantly broadening its commercial potential beyond the initial approved indication. Rasonque was approved by the FDA in late August for adults with metastatic pancreatic adenocarcinoma, priced at $39,800 for a 30-day supply.

Several major banks have raised their price targets in recent weeks: BofA Securities to $265, Jefferies to $270, UBS to $265, Morgan Stanley initiated coverage at Overweight with a $255 target, and RBC raised to $251. RBC projects approximately $249 million in US sales for Rasonque this year, citing rapid adoption driven by strong physician awareness and limited alternative therapies. Morgan Stanley models approximately $12 billion in peak risk-adjusted sales across the company's portfolio by 2036.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)